Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Drug Treats Rare Genetic Overgrowth Disorder.

The American journal of nursing - 1 Aug 2022

Aschenbrenner Diane S

Abstract excerpt

The Food and Drug Administration has approved alpelisib (Vijoice) to treat a rare noninherited genetic disorder called PIK3CA-related overgrowth spectrum.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Pharmaceutical Preparations
Share to Rare Diseases
Share to United States

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35862598
DOI: 10.1097/01.NAJ.0000854968.37305.7a

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Drug Treats Rare Genetic Overgrowth Disorder.PMID 35862598Read ↗

Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North AmericaSemantic proximity Read ↗

Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum.Semantic proximity Read ↗

Four-month-old with severe PIK3CA-related overgrowth spectrum disorder successfully treated with alpelisb.Semantic proximity Read ↗

PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With AlpelisibSemantic proximity Read ↗

Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.Semantic proximity Read ↗

Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndromeSemantic proximity Read ↗

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.Semantic proximity Read ↗

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrumSemantic proximity Read ↗

Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).Semantic proximity Read ↗

Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.Semantic proximity Read ↗

Response to Alpelisib in Clinically Distinct Pediatric Patients With PIK3CA -related Disorders.Semantic proximity Read ↗

PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.